drugset
drugset / Trial / NCT01269294

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

NCT01269294 ↗

Phase 1 Completed 60 enrolled Tibotec Pharmaceuticals, Ireland
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of TMC435 on the results of electrocardiograms (ECGs) in healthy volunteers. An electrocardiogram is an electric recording of the heart. TMC435 is being investigated for the treatment of chronic hepatitis C virus infection.

Timeline

Start
2011-01
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg Oral
Subject Simeprevir Small molecule 150 mg Oral
Subject Simeprevir Small molecule 350 mg Oral

Indications

chronic hepatitis C virus infection